**DISORDERS OF ADRENAL GLANDS AND SEX DEVELOPMENT IN CHILDREN: INSIGHTS FROM THE TROPICS**

**Nishant Raizada MD, DM Endocrinology, Associate Professor and Head,** Department of Endocrinology, Center for Diabetes, Endocrinology and Metabolism, University College of Medical Sciences and Guru Teg Bahadur Hospital, Delhi, India. [drnishantraizada@gmail.com](mailto:drnishantraizada@gmail.com)

**Phibakordor L. Nonglait MD, Senior Resident,** Department of Endocrinology, Center for Diabetes, Endocrinology and Metabolism, University College of Medical Sciences and Guru Teg Bahadur Hospital, Delhi, India. phiba27@gmail.com

**Received May 17, 2023**

**ABSTRACT**

The adrenal gland is essential for survival and its function is compartmentalized into specific zones. Disorders of the adrenal gland can be classified as those affecting the adrenal cortex or medulla. Pediatric adrenal disorders can have distinct presentations and etiologies in comparison to adults, such as adrenal insufficiency associated with genetic syndromes or Cushing’s syndrome associated with adrenocortical tumors and primary pigmented nodular adrenocortical disease. Congenital adrenal hyperplasia (CAH) has been commonly reported from the tropics, and rare variants of CAH have also been recognized in populations where consanguinity is prevalent. Pheochromocytomas and paragangliomas (PPGL) have been reported from tropical countries, some with rare presentations. The frequent rate of heritability and mutations in PPGL highlights the importance of genetic studies among children. The role of functional imaging is evolving for PPGLs as data is emerging from cohort studies. Disorders of Sex Development (DSD) comprise a heterogeneous group of disorders that can present in any age group. DSDs in childhood usually present with ambiguous genitalia and a multidisciplinary approach is required for its management. The diagnosis of adrenal disorders can sometimes pose a challenge in tropical countries due to resource constraints, lack of awareness, and access to medical care. However, available data from cohort studies and case reports have highlighted differences in etiology and presentation as compared to other parts of the world and the need for further studies.

**INTRODUCTION**

Adrenal disorders commonly seen in the tropics include adrenal insufficiency, congenital adrenal hyperplasia, adrenal Cushing’s syndrome, and pheochromocytoma/paragangliomas

**Adrenal Insufficiency**

It is characterized by decreased production of cortisol by the adrenals. The identification of adrenal insufficiency in children requires a high index of suspicion. This is important not only to prevent an adrenal crisis but to identify the associated comorbidities. Acute adrenal crisis can present in infancy as a salt-wasting crisis or precipitated in children due to stressors such as illness, trauma, or surgery. They often present as an emergency with abdominal pain, vomiting, hypotension, hypoglycemia with seizures, and hyponatremia which eventually leads to shock and cardiovascular collapse if undiagnosed. Chronic adrenal insufficiency presents as prolonged neonatal jaundice, failure to thrive, hyperpigmentation, anorexia, fatigue, nausea and vomiting, salt craving, diarrhea, abdominal pain, postural hypotension, and tachycardia. A study from Pakistan characterized the presentation of children with adrenal insufficiency of which 19% presented with an adrenal crisis following an acute illness (1). The chronic symptoms reported were not different from that seen in another cohort form South Africa (2). Rare primary presentations of adrenal insufficiency as infantile cholestasis (3) and gigantism with motor delay have been reported (4).

The causes of adrenal insufficiency in children are different as compared to adults. Etiologically it can be divided into primary and secondary adrenal insufficiency. It can also be seen as an isolated condition or in association with specific syndromes.

Primary adrenal insufficiency may be related to an underlying genetic or metabolic cause. Congenital Adrenal Hyperplasia (CAH) is the most common cause of primary adrenal insufficiency. Autoimmunity, infections, and hemorrhage are also important causes of primary adrenal insufficiency. The largest cohort study from Sudan diagnosed 80 children with adrenal insufficiency. The etiology ranged from Allgrove syndrome (36%), auto-immune polyendocrinopathy syndrome (11%), adrenoleukodystrophy (9 %), bilateral hemorrhage (1%), to unspecified (42%) (5). Case reports and series also reported similar causes such as Allgrove syndrome (6-8), adrenoleukodystrophy (9), to rare causes such as familial primary glucocorticoid deficiency (3), Steroidogenic acute regulatory protein (StAR) deficiency (10), Nuclear receptor subfamily 0, group B, member 1 (NR0B1) gene or DAX1 gene mutation (11) as well as primary multidrug-resistant adrenal tuberculosis (12).

The diagnosis of adrenal insufficiency is made by a peak cortisol value less than 18 mcg/dl on ACTH (Synacthen) stimulation test. A raised plasma ACTH level confirms primary adrenal insufficiency. The dose of Synacthen recommended for children less than 2 years is 15 µg/kg body weight and for children more than 2 years 250 µg im. However, Synacthen is not easily available in many countries. Acton Prolongatum, a long-acting synthetic ACTH preparation of the 39-amino acid native porcine sequence in a carboxymethylcellulose base has been studied and validated in India for the diagnosis of adrenal insufficiency in children > 5 years (13).

|  |  |
| --- | --- |
| **Table 1. Acton Prolongatum (ACTH Stimulation) Test** | |
| **Indication** | To diagnose adrenal insufficiency \* |
| **Preparation** | Injection Acton Prolongatum® Ferring pharmaceuticals (Saint Prex, Switzerland) is available as a 5-mL vial with a concentration of 60 IU/mL.  To prepare 25 IU\*\* of Acton Prolongatum, 0.4 ml of Acton Prolongatum is taken in 1 ml syringe and diluted with 0.5 ml NS |
| **Performing the test** | After overnight fast, basal sample for cortisol is taken at 8 AM and 25 IU of Acton Prolongatum is injected intramuscularly over the deltoid.  One hour (9 AM) post stimulation, a second cortisol sample is taken |
| **Interpretation** | Peak cortisol (at 60 minutes) <18 mcg/dl: suggestive of adrenal insufficiency (94% specific and 57% sensitive)  Peak cortisol (at 60 minutes) >22 mcg/dl : rules out adrenal insufficiency |

NB: \* Test is validated for children above 5 years (13). \*\* Studies in adults have also been done with 30 IU of Acton Prolongatum (0.5 ml) (95) (96).

**Congenital Adrenal Hyperplasia**

CAH is a group of autosomal recessive disorders characterized by enzymatic defects in adrenal steroidogenesis and diminished cortisol synthesis. The accumulation of precursors proximal to the blocked pathway and hypocortisolemia are responsible for the clinical features of these disorders. The presentation is varied and includes early classic presentation of salt-wasting (SW) and simple virilizing (SV) disorder to the non-classical presentation. Rare presentations of CAH as adrenal insufficiency (14), genital ambiguity (15) (16), hypoglycemia (17, 18), and precocious puberty (19) due to enzyme defects other than 21 hydroxylase deficiency have also been reported.

Newborn screen (NBS) for CAH from India revealed a prevalence of 1 in 576 (20). However retrospective data in the absence of NBS revealed the presentation of adrenal crisis in >80% of subjects with 70% presenting as SW-CAH and a delayed diagnosis in boys as compared to girls highlighting the importance of NBS (21).

CAH due to 21 hydroxylase deficiency (21OHD) accounts for 90-95% of the cases followed by 11β-hydroxylase deficiency (11βOHD), and 3β-hydroxysteroid dehydrogenase 2 (3βHSD2). Regional differences in the prevalence of enzyme deficiencies confirmed by genetic tests have been described from Cameroon (n=24) which found that 11βOHD was more common (66.6%) followed by 21OHD and as well from Algeria (n=273) which showed that 3βHSD2 (5%) was the second most common form after 21OHD. These differences may be attributed to the founder mutations (22, 23).

Diagnosis is made by screening for 17 OH Progesterone (OHP) which is elevated, followed by 17 OHP and other steroid responses to synacthen test. However, confirmation of specific enzyme deficiency requires genetic testing. The spectrum of genetic mutations has been described in various cohorts for CYP21A2, which was able to diagnose mutations in 80-96% of the subjects, and genotype-phenotype correlations have been established for various forms of CAH (24-27). Additionally, allele-specific PCR for screening common CYP21A2 mutations has been suggested as a cost-effective tool, especially in resource-constraint settings (28). The diagnosis of other enzyme deficiencies is often challenging due to a lack of genetic tests and steroid precursor assays. However, studies are emerging for other CAH variants such as 11βOHD from India (29) and 3β-hydroxysteroid dehydrogenase 2 (3βHSD2) deficiency from Algeria (23) with the discovery of novel mutations indicating genetic heterogeneity. Combined genetic mutations have also been reported (30).

A child diagnosed with CAH requires lifelong treatment and monitoring. A longitudinal data from Egypt indicated that CAH subjects with older age, poor hormonal control, and frequent hospitalizations have relatively poorer health-related quality of life. The challenges faced in the management of CAH include late diagnosis, poor follow-up (31), and the development of adrenal rest tumors (23, 29).

**Cushing Syndrome**

Cushing syndrome is suspected in a child who presents with weight gain and growth failure. The characteristic cushingoid features described in adults are usually not seen and they often present with generalized obesity. Endogenous Cushing syndrome varies with the age of diagnosis with adrenal tumors predominating in children < 7 years and Cushing disease after 7 years. However, it is important to note that the most common cause of Cushing’s syndrome is exogenous and even topical routes of administration have been implicated in children (32-34).

Of the ACTH-independent Cushing syndrome, primary pigmented nodular adrenocortical disease (PPNAD) has been the most frequently described from the tropics in case series and reports some of which have been found in association with Carney’s complex (35-39). The other important cause reported is in association with Adrenocortical tumors as described below.

**Adrenocortical Tumors**

These tumors account for 0.2% of all pediatric tumors. The largest case series from India with 17 cases reported that 82% presented with endocrine dysfunction, of which the most common was Cushing syndrome with or without virilization seen in 53% of the subjects (40). Another cohort of 7 children from Sri Lanka also reported peripheral precocious puberty in all the subjects and one boy had the phenotypic features of Beckwith–Wiedemann syndrome (41). Case reports have also reported similar presentations some of which are the rare variants of adrenocortical oncocytoma (42-49). Large non-functioning adrenal cortical carcinoma can present with mass effects without any features (40, 50). The prognosis depends on the diagnosis with adenomas having complete remission. However, the prognosis of subjects with carcinoma was poor (40) (41).

**Pheochromocytomas and Paragangliomas**

Pheochromocytoma (PCC) refers to the catecholamine-producing tumor of the adrenal medulla whereas paragangliomas (PGL) are extra-adrenal tumors of sympathetic and parasympathetic ganglia. Of the PPGLs, 10-20% occur in the pediatric age group. There is a high rate of germline mutations and heritability in pediatric PPGLs. A cohort of 30 children from India with PPGL showed that 26.7% of the subjects had syndromic or familial association, of which Von Hippel-Lindau was the most common. Fourteen (46.7%) children had germline mutations (VHL 10 (33.3%), SDHB 2 (6.6%), and SDHD 2 (6.6%). Bilateral pheochromocytomas and symptomatic presentation was more frequent in children as compared to adult PPGL. Children with VHL mutation had more frequent bilateral PCC, coexisting PGL and recurrence (51).

PPGLs often mimic other diseases and rare presentations such as myocarditis (52), diabetes insipidus (53), hypertensive encephalopathy (54) (55), Cushing syndrome (56), pseudo renal artery stenosis (57), and papilledema (58) have been described.

After biochemical confirmation, imaging studies are advised for anatomical localization. Functional imaging is recommended for larger tumors, suspected multifocal or extra adrenal tumors, succinate dehydrogenase subunit B (SDHB) or alpha-thalassemia/mental retardation syndrome X-linked mutations (ATRX) and dopamine secreting PPGLs. A cohort study from India revealed that 68Ga-DOTATATE PET/CT (95%) had a higher sensitivity than 18F-FDG-PET/CT (80%) and 131I-MIBG (65%) for overall lesions. 68Ga-DOTATATE PET/CT was more sensitive than 131I-MIBG (93 vs. 42%) for detecting metastases (59). The definitive management of PPGL is surgical resection. Pre-operative preparation with experienced anesthetic (60) and surgical team (61) is important for successful outcomes following surgery. The management of metastatic PPGL is challenging especially in countries with limited resources. Fractionated low dose 131 I-metaiodobenzylguanidine (MIBG) therapy has been used in the treatment of metastatic paraganglioma (62). Lifelong surveillance is recommended in children to detect early recurrence (63).

**DISORDERS OF SEX DEVELOPMENT (DSD)**

DSD is a condition in which chromosomal, gonadal, or anatomical sex is atypical (64). Observational studies from Egypt and Cameroon reported that these constitute 2-9.4% of the subjects presenting to endocrine clinics (65, 66).

**Epidemiology**

DSDs can be broadly classified into sex chromosomes, 46 XX and 46 XY DSDs. Cohort studies have revealed a prevalence of 5-15 % for sex chromosomal DSDs, 33.7-71% for 46 XY DSD, and 24-51% for 46 XX DSD (65-67). Regional differences were observed in the prevalence of these disorders attributed to consanguinity and endogamous marriages (66).

|  |  |  |
| --- | --- | --- |
| **Table 2. Classification of DSDs** | | |
| **SEX CHROMOSOME DSD** | **46 XY DSD** | **46 XX DSD** |
| Turner’s syndrome (and 45X variants) | **Disorders of testis development**  Complete testicular dysgenesis (Swyer syndrome)  Partial gonadal dysgenesis  Testicular regression | **Disorders of ovarian development**  Gonadal dysgenesis  Ovotesticular DSD   * RSPO gene mutation * NR5A1 gene mutation   Testicular DSD   * SRY+ * SOX9/SOX3 duplication * WNT 4 mutation |
| Klinefelter’s syndrome (and 47XXY variants) | **Disorders of androgen synthesis**  STAR mutation  CAH   * 3β-hydroxysteroid dehydrogenase 2 * 17α-hydroxylase/17,20-lyase * P450 oxidoreductase   Isolated testosterone deficiency   * 17β-hydroxysteroid dehydrogenase * 5α-reductase 2 | **Androgen excess**  CAH   * 21-hydroxylase * 3β-hydroxysteroid dehydrogenase 2 * P450 oxidoreductase * 11β-hydroxylase * Glucocorticoid receptor mutations   Maternal   * Virilising tumors * Exogenous androgens |
| Mixed gonadal dysgenesis Ovotesticular DSD | **Disorders of androgen action**  Androgen insensitivity syndrome  Luteinizing hormone receptor defects | **Others**  Mullerian agenesis (MRKH syndrome)  Uterine abnormalities  Syndromic associations (cloacal exostrophy) |
|  | **Others**  Persistent mullerian duct syndrome  Complex syndromic disorders  Isolated hypospadias |  |

**Clinical Features**

DSDs have a varied presentation which includes ambiguous genitalia of varying severity, primary amenorrhea, and virilization at puberty to infertility in adulthood. The recognition of DSDs has critical implications due to their syndromic associations such as Wilm’s tumor and renal failure with Denys-Drash syndrome, adrenal insufficiency with CAH, and future risk of gonadoblastoma. In addition, there are long-term social and psychological impacts such as gender of rearing and fertility prospects.

46 XY DSD

46 XY DSD can be classified as disorders of testis development, androgen synthesis, or androgen action.

The most common DSD reported among these are disorders of androgen synthesis of which 5 alpha reductase deficiency is the most commonly reported with a prevalence of 10%- 33% with a presentation as ambiguous genitalia (65-68). The higher rates reported in recent literature are attributed to the genetic confirmation some of which are novel and founder mutations, as opposed to the earlier diagnosis based on biochemical ratios of Testosterone: Dihydrotestosterone (69-71). Rare variants of CAH with presentation as infertility, hypertension, or virilization been reported (15, 72-74).

Androgen insensitivity syndrome (AIS); partial (PAIS) or complete (CAIS) is the next most commonly reported 46 XY DSD from various countries with a prevalence of 5-28% (65-67, 75, 76). However, cohort studies with genetic confirmation reported a prevalence of 10-38% (77, 78). A point to be noted was that only 31% of patients with a provisional diagnosis of PAIS had pathogenic variants in the AR gene (78). Patients with CAIS are reared as females and have a later presentation with primary amenorrhea. The presentation of PAIS may be earlier with atypical genitalia or gynecomastia.

The third most commonly reported cause is gonadal dysgenesis which can be partial or complete with a prevalence of 4-10% (65-67, 79), Case reports of gonadal development disorders with dysgenesis are also emerging which include WT-1 mutation (80-82), Desert hedgehog (DHH) gene (83), and Mitogen‐activated protein 3 kinase 1 (MAP3K1) gene (84).

Other rare causes such as persistent Mullerian duct syndrome (85, 86) and Leydig cell hypoplasia (87) have been reported from the Middle-eastern countries.

Syndromic causes of 46 XY DSD accounts for 1-1.8% of the cohort studies cited earlier.

46 XX DSD

In contrast to the 46 XY DSDs which can have variable presentation and etiology, the most common cause of 46 XX DSD is CAH of which 21 hydroxylase deficiency is the most common cause. However, Sap et al from Cameroon reported 11 hydroxylase was the most common cause of CAH in their population (66). The prevalence of 46 XX DSD ranges from 20%-55% (65-67).

The other important causes of 46 XX DSD are ovotesticular DSD (16.2%) and vaginal atresia (2%). Rare case reports of aromatase deficiency (88) and isodicentric Y chromosome in 45 X individuals have been reported (89).

**Management**

The diagnosis and management of DSDs are challenging, especially in countries with low resources. The most important step in the initial evaluation of ambiguous genitalia is the presence of gonads which gives us a clue in narrowing the cause and guiding further workup. Karyotyping, imaging by pelvic USG or MRI, followed by biochemical evaluation helps in establishing a diagnosis. The emergence of genetic tests has further simplified the evaluation of such patients and will prove to be a valuable tool in the future.

Diagnosis of DSD and gender assignment has lifelong implications for the patients. There have been reports of gender change and gender identity confusion especially in 46 XY DSDs (90-92). However, patients with AIS have less prevalence of gender dysphoria (77, 92).

For 46 XX DSDs with virilization, feminizing genitoplasty is an important concern especially the timing of surgery. An observational study from Malaysia of 59 females with CAH who had undergone feminizing genitoplasty (FG) reported that infancy and early childhood as the best timing for first FG, most preferring single-stage over 2-stage surgery (93).

Data regarding the risk of gonadoblastoma and prophylactic gonadectomy is scarce. A case series of 5 subjects of 46 XY DSD reared as females revealed malignancy in only one patient with CAIS (94).

**REFERENCES**

1. Laghari TM, Ibrahim MN, Khoso Z, Hanif MI, Meher-Un-Nisa null, Raza J. Spectrum of Addison’s Disease in Children. J Coll Physicians Surg--Pak JCPSP. 2020 Oct;30(10):1086–9.

2. Ross IL, Levitt NS. Addison’s disease symptoms--a cross sectional study in urban South Africa. PloS One. 2013;8(1):e53526.

3. Alsaedi A, Kamal NM, Bakkar A, Althobaiti E, Naeem M, Kamal M. Novel Melano-Cortin-2-Receptor Gene Mutation Presenting With Infantile Cholestasis: A Case Report. Clin Med Insights Case Rep. 2022;15:11795476221091388.

4. Uyangoda K, Kamalanathan P, Mettananda S. Familial glucocorticoid deficiency presenting with hyperpigmentation, gigantism, and motor development delay: a case report. J Med Case Reports. 2019 Sep 4;13(1):280.

5. Musa SA, Hassan SS, Ahmed AI, Ngwiri T, Fadlalbari GF, Ibrahim AA, et al. Clinical profile, etiology, and diagnostic challenges of primary adrenal insufficiency in Sudanese children: 14-years’ experience from a resource limited setting. J Pediatr Endocrinol Metab. 2022 Feb 1;35(2):231–7.

6. Singh K, Puri RD, Bhai P, Arya AD, Chawla G, Saxena R, et al. Clinical heterogeneity and molecular profile of triple A syndrome: a study of seven cases. J Pediatr Endocrinol Metab. 2018 Jul 1;31(7):799–807.

7. Jayant SS, Gupta R, Agrawal K, Das L, Dutta P, Bhansali A. Triple A (Allgrove) syndrome due to AAAS gene mutation with a rare association of amyotrophy. Horm Athens Greece. 2021 Mar;20(1):197–205.

8. Yadav P, Kumar D, Bohra GK, Garg MK. Triple A syndrome (Allgrove syndrome) - A journey from clinical symptoms to a syndrome. J Fam Med Prim Care. 2020 May;9(5):2531–4.

9. Supornsilchai V, Wacharasindhu S, Desudchit T. Adrenal functions in children with adrenoleukodystrophy. J Med Assoc Thail Chotmaihet Thangphaet. 2002 Jun;85 Suppl 1:S286-292.

10. Achermann JC, Meeks JJ, Jeffs B, Das U, Clayton PE, Brook CGD, et al. Molecular and Structural Analysis of Two Novel STAR Mutations in Patients with Lipoid Congenital Adrenal Hyperplasia. Mol Genet Metab. 2001 Aug 1;73(4):354–7.

11. Mohan S, Danda S, Mathai S, Simon A. Novel mutation in the nuclear receptor subfamily 0, group B, member 1 (*NR0B1*) gene associated with intrafamilial heterogeneity in three boys with X-linked adrenal hypoplasia congenita and hypogonadotropic hypogonadism from India. Natl Med J India. 2019 May 1;32:141.

12. Sharma S, Joshi R, Kalelkar R, Agrawal P. Tuberculous Adrenal Abscess Presenting as Adrenal Insufficiency in a 4-Year-Old Boy. J Trop Pediatr. 2019 Jun 1;65(3):301–4.

13. Sharma R, Madathil S, Maheshwari V, Roy K, Kumar B, Jain V. Long-acting intramuscular ACTH stimulation test for the diagnosis of secondary adrenal insufficiency in children. J Pediatr Endocrinol Metab. 2019 Jan 28;32(1):57–63.

14. Sarathi V, Nagalingam C. Normal male external genitalia do not rule out CYP11A1 deficiency. BMJ Case Rep. 2019 Jul;12(7):e228235.

15. Pant V, Baral S, Shrestha B, Tumbapo A. A child with hypertension and ambiguous genitalia - an uncommon variant of congenital adrenal hyperplasia: a case report. J Med Case Reports. 2017 Jun 23;11(1):168.

16. Sheikh WH, Asif N, Younas M, Basharat N, Qurat-Ul-Ain null, Noreen null. A Child with Ambiguous Genitalia: An Atypical Presentation. J Coll Physicians Surg--Pak JCPSP. 2019 Jun;29(6):S54–5.

17. Garg M, Chugh V, Dutt Sharma S, Mitharwal P, Mangla A. Non-classical lipoid adrenal hyperplasia presenting as hypoglycemic seizures. J Pediatr Endocrinol Metab JPEM. 2020 Nov 26;33(11):1507–9.

18. Konar MC, Goswami S, Babu BG, Mallick AK. Hypoglycemia due to 3β-Hydroxysteroid Dehydrogenase type II Deficiency in a Newborn. Indian Pediatr. 2015 Nov;52(11):981–3.

19. Majumder S, Chakraborty PP, Ghosh PC, Bera M. Differentiating 11β-hydroxylase deficiency from primary glucocorticoid resistance syndrome in male precocity: real challenge in low-income countries. BMJ Case Rep. 2020 Feb 28;13(2):e233722.

20. ICMR Task Force on Inherited Metabolic Disorders. Newborn Screening for Congenital Hypothyroidism and Congenital Adrenal Hyperplasia. Indian J Pediatr. 2018 Nov;85(11):935–40.

21. Seneviratne SN, Sandakelum U, Jayawardena CH, Weerasinghe AM, Wickramarachchi PS, Silva S de. Presenting status of children with classical congenital adrenal hyperplasia over two decades (1999–2018) in the absence of newborn screening in Sri Lanka. J Pediatr Endocrinol Metab. 2021 Sep 1;34(9):1131–7.

22. Um SSN, Betoko RM, Mekone I, Chetcha AB, Tardy V, Dahoun S, et al. Clinical, biochemical, and biomolecular aspects of congenital adrenal hyperplasia in a group of Cameroonian children and adolescents. J Pediatr Endocrinol Metab. 2022 Jun 1;35(6):777–83.

23. Ladjouze A, Donaldson M, Plotton I, Djenane N, Mohammedi K, Tardy-Guidollet V, et al. Genotype, Mortality, Morbidity, and Outcomes of 3β-Hydroxysteroid Dehydrogenase Deficiency in Algeria. Front Endocrinol. 2022 Jun 10;13:867073.

24. Khan AH, Nasir MI, Moatter T. Characterization of pathogenic mutations in 21-hydroxylase gene of Pakistani patients with congenital adrenal hyperplasia and their family members--a preliminary report. JPMA J Pak Med Assoc. 2002 Jul;52(7):287–91.

25. Ganesh R, Suresh N, Janakiraman L, Ravikumar K. CYP21A2 gene mutation in South Indian children with congenital adrenal hyperplasia. Indian Pediatr. 2015 Aug;52(8):710–1.

26. Khajuria R, Walia R, Bhansali A, Prasad R. The spectrum of CYP21A2 mutations in Congenital Adrenal Hyperplasia in an Indian cohort. Clin Chim Acta. 2017 Jan;464:189–94.

27. Essawi M, Mazen I, Fawaz L, Hassan H, ElBagoury N, Peter M, et al. Assessment of the most common CYP21A2 point mutations in a cohort of congenital adrenal hyperplasia patients from Egypt. J Pediatr Endocrinol Metab JPEM. 2020 Jul 28;33(7):893–900.

28. Ravichandran L, Korula S, Asha HS, Varghese D, Parthiban R null, Johnson J, et al. Allele-specific PCR and Next-generation sequencing based genetic screening for Congenital Adrenal Hyperplasia in India. Eur J Med Genet. 2021 Dec;64(12):104369.

29. Karlekar MP, Sarathi V, Lila A, Rai K, Arya S, Bhandare VV, et al. Expanding genetic spectrum and discriminatory role of steroid profiling by LC-MS/MS in 11β-hydroxylase deficiency. Clin Endocrinol (Oxf). 2021 Apr;94(4):533–43.

30. Aljabri A, Alnaim F, Alsaleh Y. Combined homozygous 21 hydroxylase with heterozygous P450 oxidoreductase mutation in a Saudi boy presented with hypertension. BMJ Case Rep. 2020 Sep 29;13(9):e233942.

31. Maiti A, Chatterjee S. Congenital adrenal hyperplasia: An Indian experience: Congenital adrenal hyperplasia Indian series. J Paediatr Child Health. 2011 Dec;47(12):883–7.

32. Alkhuder L, Mawlawi H. Infantile Iatrogenic Cushing Syndrome due to Topical Steroids. Case Rep Pediatr. 2019 Dec 2;2019:2652961.

33. Oluwayemi IO, Oduwole AO, Oyenusi E, Onyiriuka AN, Abdullahi M, Fakeye-Udeogu OB, et al. Iatrogenic Cushing’s syndrome in children following nasal steroid. Pan Afr Med J. 2014;17:237.

34. Dutta D, KS S, Ghosh S, Mukhopadhyay S, Chowdhury S. Iatrogenic Cushing’s Syndrome Following Short-Term Intranasal Steroid Use. J Clin Res Pediatr Endocrinol. 2012 Sep;4(3):157–9.

35. Jeyaraman K, Jyotsna VP, Ammini AC. A Child with Cushing’s Syndrome – Etiological Clue from Adrenal Imaging (Pediatric Cushing’s Syndrome). J Pediatr Endocrinol Metab [Internet]. 2010 Jan [cited 2023 May 5];23(12). Available from: https://www.degruyter.com/document/doi/10.1515/jpem.2010.195/html

36. Patarakijvanich N, Kayasut K, Mitarnun W, Pathrapinyokul S, Ayudya SSN. Primary pigmented nodular adrenocortical disease with synaptophysin immunoreactivity in two thai children. J Med Assoc Thail Chotmaihet Thangphaet. 2007 Jun;90(6):1208–13.

37. Memon SS, Thakkar K, Patil V, Jadhav S, Lila AR, Fernandes G, et al. Primary pigmented nodular adrenocortical disease (PPNAD): single centre experience. J Pediatr Endocrinol Metab. 2019 Apr 1;32(4):391–7.

38. Alruwaili TK, Alkanhal KI, AlShoomi AM, Almanie DA, Alahmed MH. A 14-Year-Old Saudi Boy with Gynecomastia, Cushing Syndrome, Large-Cell Calcifying Sertoli Cell Tumor of the Testis, and Carney Complex. Am J Case Rep. 2022 Dec 27;23:e937404.

39. Oza CM, Mehta S, Khadilkar V, Khadilkar A. Primary pigmented nodular adrenal disease presenting as hypertensive crisis. BMJ Case Rep. 2022 Jun 1;15(6):e250023.

40. Das S, Sengupta M, Islam N, Roy P, Datta C, Mishra PK, et al. Weineke criteria, Ki-67 index and p53 status to study pediatric adrenocortical tumors: Is there a correlation? J Pediatr Surg. 2016 Nov;51(11):1795–800.

41. Naotunna NPGCR, Siriwardana HVDN, Lakmini BC, Gamage DS, Gunarathna S, Samarasinghe M, et al. Adrenocortical tumors in children: Sri Lankan experience from a single center, and a mini review. J Med Case Reports. 2023 Apr 13;17:137.

42. Regmi N, Al-Nahian S. A rare form of Cushing’s syndrome in a 10 year old child. J Nepal Health Res Counc. 2013 Sep;11(25):296–9.

43. Al Badi MK, Al-Alwan I, Al-Dubayee M, Al-Anzi A, Al Turki MS, Aloudah N, et al. Testosterone- and Cortisol-secreting Oncocytic Adrenocortical Adenoma in the Pediatric Age-group. Pediatr Dev Pathol Off J Soc Pediatr Pathol Paediatr Pathol Soc. 2018;21(6):568–73.

44. Narayanan N, Kamalanathan S, Sahoo J, Naik D, Kumaravel S, Ganesh RN. Pediatric Adrenocortical Oncocytoma presenting as Cushing’s Syndrome and Peripheral Precocious Puberty: A Case Report and Review of Literature. J ASEAN Fed Endocr Soc. 2021;36(2):205–8.

45. Mittal A, Aggarwal M, Debata P. Large adrenocortical carcinoma presenting as an adenoma with precocious puberty. Indian J Pediatr. 2012 Jun;79(6):820–1.

46. Pal DK, Kundu AK, Chakrabortty S, Das S. Virilising adrenocortical carcinoma. J Indian Med Assoc. 2002 Apr;100(4):251–2.

47. Subbiah S, Nahar U, Samujh R, Bhansali A. Heterosexual precocity: rare manifestation of virilizing adrenocortical oncocytoma. Ann Saudi Med. 2013;33(3):294–7.

48. Kanjilal B, Ghosh M, Mitra A, Kar S, Bisht J, Das RN, et al. Cytological diagnosis of adrenocortical carcinoma: A report of 2 cases in children. Diagn Cytopathol. 2018 Dec;46(12):1064–7.

49. Verma S, Mandelia A, Jain M, Bhatia V, Lal H. Feminizing adrenocortical oncocytoma presenting as precocious puberty: a case report and literature review. J Pediatr Endocrinol Metab JPEM. 2022 Jun 27;35(6):827–30.

50. Mirsharifi A, Vasei M, Sadeghian E, Ghorbani-Abdehgah A, Naybandi Atashi S. Extra-adrenal, non-functional adrenocortical carcinoma presenting with acute abdomen: a case report. J Med Case Reports. 2020 Jul 8;14(1):107.

51. Khadilkar K, Sarathi V, Kasaliwal R, Pandit R, Goroshi M, Shivane V, et al. Genotype-phenotype correlation in paediatric pheochromocytoma and paraganglioma: a single centre experience from India. J Pediatr Endocrinol Metab JPEM. 2017 May 1;30(5):575–81.

52. Molaei A, Abarzadeh-Bairami V, Sadat-Ebrahimi SR. A case of pheochromocytoma presenting with cardiac manifestation: case report. BMC Pediatr. 2020 Jun 17;20(1):299.

53. Jain V, Yadav J, Satapathy AK. Pheochromocytoma presenting as diabetes insipidus. Indian Pediatr. 2013 Nov 8;50(11):1056–7.

54. Aftab S, Yasmeen T, Hamid MH, Sarwar M, Sipra H, Qureshi A, et al. Pheochromocytoma: a rare cause of childhood hypertensive encephalopathy. J Coll Physicians Surg--Pak JCPSP. 2012 Aug;22(8):536–8.

55. Yeung L, Kwan E, Cheung P, Low L. Phaeochromocytoma in children.

56. Kumar M, Kumar V, Talukdar B, Mohta A, Khurana N. Cushing syndrome in an infant due to cortisol secreting adrenal pheochromocytoma: a rare association. J Pediatr Endocrinol Metab JPEM. 2010 Jun;23(6):621–5.

57. Vaze D, Trehan A, Saxena A, Joshi K, Narasimhan KL. Extraadrenal Pheochromocytoma With Renal Artery “Pseudostenosis”—An Important Pitfall. Urology. 2012 Oct;80(4):925–7.

58. Ba-Abbad RA, Nowilaty SR. Bilateral Optic Disc Swelling as the Presenting Sign of Pheochromocytoma in a Child. Medscape J Med. 2008 Jul 29;10(7):176.

59. Jaiswal SK, Sarathi V, Malhotra G, Hira P, Shah R, Patil VA, et al. The utility of 68Ga-DOTATATE PET/CT in localizing primary/metastatic pheochromocytoma and paraganglioma in children and adolescents - a single-center experience. J Pediatr Endocrinol Metab JPEM. 2021 Jan 27;34(1):109–19.

60. Maurya RG, Gautam S, Singh GP, Srinivas C. Anaesthetic challenges in perioperative management of thoracic paraganglioma in an 8-year-old child. BMJ Case Rep. 2021 Aug;14(8):e243521.

61. Singh J, Rana SS, Sharma R, Ghai B, Puri GD. A rare cause of hypertension in children: intrathoracic pheochromocytoma. Pediatr Surg Int. 2008 Jul;24(7):865–7.

62. Basu S, Nair N. Stable disease and improved health-related quality of life (HRQoL) following fractionated low dose 131I-metaiodobenzylguanidine (MIBG) therapy in metastatic paediatric paraganglioma: observation on false “reverse” discordance during pre-therapy work up and its implication for patient selection for high dose targeted therapy. Br J Radiol. 2006 Aug;79(944):e53-58.

63. Jain V, Bishnoi A, Meena K, Aggarwal V, Chadha R, Puri A, et al. Metachronous occurrence of multifocal phaeochromocytoma. Indian J Pediatr. 2011 May;78(5):620–2.

64. Hughes IA, Houk C, Ahmed SF, Lee PA, LWPES Consensus Group, ESPE Consensus Group. Consensus statement on management of intersex disorders. Arch Dis Child. 2006 Jul;91(7):554–63.

65. Shamma RA, Atef S, Arafa N. Etiological classification and clinical spectrum of Egyptian pediatric patients with disorder of sex development, single center experience. Endokrynol Pol. 2021;72(5):558–65.

66. Sap SNU, Mbono Betoko R, Etoa Etoga M, Mure PY, Morel Y, Dahoun S, et al. Observational study of disorders of sex development in Yaounde, Cameroon. J Pediatr Endocrinol Metab JPEM. 2020 Mar 26;33(3):417–23.

67. Joshi RR, Rao S, Desai M. Etiology and clinical profile of ambiguous genitalia an overview of 10 years experience. Indian Pediatr. 2006 Nov;43(11):974–9.

68. Di Marco C, Bulotta AL, Varetti C, Dosa L, Michelucci A, Baldinotti F, et al. Ambiguous external genitalia due to defect of 5-α-reductase in seven Iraqi patients: prevalence of a novel mutation. Gene. 2013 Sep 10;526(2):490–3.

69. Kumar A, Sharma R, Faruq M, Suroliya V, Kumar M, Sharma S, et al. Spectrum of Pathogenic Variants in *SRD5A2* in Indian Children with 46,XY Disorders of Sex Development and Clinically Suspected Steroid 5α-Reductase 2 Deficiency. Sex Dev. 2019;13(5–6):228–39.

70. Arya S, Tiwari A, Lila AR, Sarathi V, Bhandare VV, Kumbhar BV, et al. Homozygous p.Val89Leu plays an important pathogenic role in 5α-reductase type 2 deficiency patients with homozygous p.Arg246Gln in SRD5A2. Eur J Endocrinol. 2020 Sep;183(3):275–84.

71. Rafigh M, Salmaninejad A, Sorouri Khorashad B, Arabi A, Milanizadeh S, Hiradfar M, et al. Novel Deleterious Mutation in Steroid-5α-Reductase-2 in 46, XY Disorders of Sex Development: Case Report Study. Fetal Pediatr Pathol. 2022 Feb;41(1):141–8.

72. Afsar J, Kachuei A, Hashemipour M, Larki-Harchegani A, Shabib S. A rare enzymatic defect, true isolated 17,20-lyase deficiency leading to endocrine disorders and infertility: case report. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol. 2020 Apr;36(4):297–302.

73. Omrani MD, Adamovic T, Grandell U, Saleh-Gargari S, Nordenskjöld A. 17-β-hydroxysteroid dehydrogenase type 3 deficiency in three adult Iranian siblings. Sex Dev Genet Mol Biol Evol Endocrinol Embryol Pathol Sex Determ Differ. 2011;5(6):273–6.

74. Maheshwari M, Arya S, Lila AR, Sarathi V, Barnabas R, Rai K, et al. 17α-Hydroxylase/17,20-Lyase Deficiency in 46,XY: Our Experience and Review of Literature. J Endocr Soc. 2022 Jan 29;6(3):bvac011.

75. Vasu VR, Saranya B, Jayashankar M, Munirajan AK, Santhiya ST. A novel splice site and two known mutations of androgen receptor gene in sex-reversed XY phenotype. Genet Test Mol Biomark. 2012 Jul;16(7):749–55.

76. Gad YZ, Mazen I, Lumbroso S, Temtamy SA, Sultan C. A novel point mutation of the androgen receptor (F804L) in an Egyptian newborn with complete androgen insensitivity associated with congenital glaucoma and hypertrophic pyloric stenosis. Clin Genet. 2003 Jan;63(1):59–63.

77. Arya S, Barnabas R, Lila AR, Sarathi V, Memon SS, Bhandare VV, et al. Clinical, Hormonal, Genetic, and Molecular Characteristics in Androgen Insensitivity Syndrome in an Asian Indian Cohort from a Single Centre in Western India. Sex Dev Genet Mol Biol Evol Endocrinol Embryol Pathol Sex Determ Differ. 2021;15(4):253–61.

78. Kumar A, Sharma R, Faruq M, Kumar M, Sharma S, Werner R, et al. Clinical, Biochemical, and Molecular Characterization of Indian Children with Clinically Suspected Androgen Insensitivity Syndrome. Sex Dev Genet Mol Biol Evol Endocrinol Embryol Pathol Sex Determ Differ. 2022;16(1):34–45.

79. Correya MA, Babu R, Archana B, Ravirajendiran S. Disorders of sexual differentiation: Report of two rare cases. Indian J Pathol Microbiol. 2021;64(2):390–3.

80. Arya S, Kumar S, Lila AR, Sarathi V, Memon SS, Barnabas R, et al. Exonic WT1 pathogenic variants in 46,XY DSD associated with gonadoblastoma. Endocr Connect. 2021 Dec 1;10(12):1522–30.

81. Mazen I, Hassan H, Kamel A, Mekkawy M, McElreavey K, Essawi M. WT1 Gene Mutation, p.R462W, in a 46,XY DSD Patient from Egypt with Gonadoblastoma and Review of the Literature. Sex Dev Genet Mol Biol Evol Endocrinol Embryol Pathol Sex Determ Differ. 2017;11(5–6):280–3.

82. Wongwaisayawan S, Boonpucknavig V, Boonpucknavig S, Hattirat P. Wilms’ tumor, male pseudohermaphroditism and glomerulonephritis: the Drash syndrome. First case report in Thailand and review the literatures. J Med Assoc Thail Chotmaihet Thangphaet. 1992 Jan;75 Suppl 1:147–52.

83. Das DK, Sanghavi D, Gawde H, Idicula-Thomas S, Vasudevan L. Novel homozygous mutations in Desert hedgehog gene in patients with 46,XY complete gonadal dysgenesis and prediction of its structural and functional implications by computational methods. Eur J Med Genet. 2011;54(6):e529-534.

84. Al Shamsi A, Al Hassani N, Hamchou M, Almazrouei R, Mhanni A. A novel missense heterozygous mutation in MAP3K1 gene causes 46, XY disorder of sex development: case report and literature review. Mol Genet Genomic Med. 2020 Sep 28;8(11):e1514.

85. Mazen I, El-Gammal M, McElreavey K, Elaidy A, Abdel-Hamid MS. Novel AMH and AMHR2 Mutations in Two Egyptian Families with Persistent Müllerian Duct Syndrome. Sex Dev Genet Mol Biol Evol Endocrinol Embryol Pathol Sex Determ Differ. 2017;11(1):29–33.

86. Farag TI. Familial persistent Müllerian Duct syndrome in Kuwait and neighboring populations. Am J Med Genet. 1993 Sep 1;47(3):432–4.

87. Hassan HA, Essawi ML, Mekkawy MK, Mazen I. Novel mutations of the LHCGR gene in two families with 46,XY DSD causing Leydig cell hypoplasia I. Horm Athens Greece. 2020 Dec;19(4):573–9.

88. Mazen I, McElreavey K, Elaidy A, Kamel AK, Abdel-Hamid MS. Aromatase Deficiency due to a Homozygous CYP19A1 Mutation in a 46,XX Egyptian Patient with Ambiguous Genitalia. Sex Dev Genet Mol Biol Evol Endocrinol Embryol Pathol Sex Determ Differ. 2017;11(5–6):275–9.

89. Mekkawy M, Kamel A, El-Ruby M, Mohamed A, Essawi M, Soliman H, et al. Isodicentric Y chromosomes in Egyptian patients with disorders of sex development (DSD). Am J Med Genet A. 2012 Jul;158A(7):1594–603.

90. Praveen EP, Desai AK, Khurana ML, Philip J, Eunice M, Khadgawat R, et al. Gender identity of children and young adults with 5alpha-reductase deficiency. J Pediatr Endocrinol Metab JPEM. 2008 Feb;21(2):173–9.

91. Ediati A, Juniarto AZ, Birnie E, Drop SLS, Faradz SMH, Dessens AB. Gender Development in Indonesian Children, Adolescents, and Adults with Disorders of Sex Development. Arch Sex Behav. 2015 Jul;44(5):1339–61.

92. Khorashad BS, Roshan GM, Reid AG, Aghili Z, Moghadam MD, Khazai B, et al. Childhood Sex-Typed Behavior and Gender Change in Individuals with 46,XY and 46,XX Disorders of Sex Development: An Iranian Multicenter Study. Arch Sex Behav. 2018 Nov;47(8):2287–98.

93. Zainuddin AA, Grover SR, Soon CH, Ghani NAA, Mahdy ZA, Manaf MRA, et al. A Multicenter Cross-Sectional Study of Malaysian Females With Congenital Adrenal Hyperplasia: Their Body Image and Their Perspectives on Feminizing Surgery. J Pediatr Adolesc Gynecol. 2020 Oct;33(5):477–83.

94. Basri NI, Soon CH, Ali A, Abdul Ghani NA, Zainuddin AA. Prophylactic gonadectomy in 46 XY females; why, where and when? Horm Mol Biol Clin Investig. 2021 Sep 24;42(3):325–8.

95. Nair A, Jayakumari C, George GS, Jabbar PK, Das DV, Jessy SJ, et al. Long acting porcine sequence ACTH in the diagnosis of adrenal insufficiency. Eur J Endocrinol. 2019 Dec;181(6):639–45.

96. Inder WJ. Long-acting porcine sequence ACTH in the diagnosis of adrenal insufficiency: a cost-effective alternative to the ACTH1-24 test. Eur J Endocrinol. 2020 Feb;182(2):C5–7.